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Abstract
Background: The production of cardiomyocytes from human induced pluripotent stem cells (hiPSC) holds great promise for
patient-specific cardiotoxicity drug testing, disease modeling, and cardiac regeneration. However, existing protocols for the
differentiation of hiPSC to the cardiac lineage are inefficient and highly variable. We describe a highly efficient system for
differentiation of human embryonic stem cells (hESC) and hiPSC to the cardiac lineage. This system eliminated the variability
in cardiac differentiation capacity of a variety of human pluripotent stem cells (hPSC), including hiPSC generated from
CD34
+ cord blood using non-viral, non-integrating methods.
Methodology/Principal Findings: We systematically and rigorously optimized .45 experimental variables to develop a
universal cardiac differentiation system that produced contracting human embryoid bodies (hEB) with an improved
efficiency of 94.762.4% in an accelerated nine days from four hESC and seven hiPSC lines tested, including hiPSC derived
from neonatal CD34
+ cord blood and adult fibroblasts using non-integrating episomal plasmids. This cost-effective
differentiation method employed forced aggregation hEB formation in a chemically defined medium, along with staged
exposure to physiological (5%) oxygen, and optimized concentrations of mesodermal morphogens BMP4 and FGF2,
polyvinyl alcohol, serum, and insulin. The contracting hEB derived using these methods were composed of high
percentages (64–89%) of cardiac troponin I
+ cells that displayed ultrastructural properties of functional cardiomyocytes and
uniform electrophysiological profiles responsive to cardioactive drugs.
Conclusion/Significance: This efficient and cost-effective universal system for cardiac differentiation of hiPSC allows a
potentially unlimited production of functional cardiomyocytes suitable for application to hPSC-based drug development,
cardiac disease modeling, and the future generation of clinically-safe nonviral human cardiac cells for regenerative
medicine.
Citation: Burridge PW, Thompson S, Millrod MA, Weinberg S, Yuan X, et al. (2011) A Universal System for Highly Efficient Cardiac Differentiation of Human
Induced Pluripotent Stem Cells That Eliminates Interline Variability. PLoS ONE 6(4): e18293. doi:10.1371/journal.pone.0018293
Editor: Martin Pera, University of Southern California, United States of America
Received December 22, 2010; Accepted February 23, 2011; Published April 8, 2011
Copyright:  2011 Burridge et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Maryland Stem Cell Research Fund (E.T.Z., L.T.), and the NHLBI Progenitor Biology Consortium (National Institutes of
Health U01HL099775 and U01HL100397 (E.T.Z)). P.W.B. and V.M. are supported by postdoctoral fellowship grants from the Maryland Stem Cell Research Fund. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ezambid1@jhmi.edu (ETZ); paul.burridge@jhmi.edu (PWB)
Introduction
Cardiac differentiation of human embryonic stem cells (hESC)
and human induced pluripotent stem cells (hiPSC) offers a
potentially unlimited source of cardiomyocytes for novel drug
discovery and testing, regenerative medicine, and the study of
human cardiac development and disease [1]. Cardiac cells
differentiated from human pluripotent stem cells (hPSC) display
normal cardiac molecular, structural and functional characteristics
[2,3,4], including the ability to respond physiologically to cardioac-
tive drugs [5]. Although hESC differentiation efficiencies up to 70%
(as assessed by the percentage of contracting hEB generated) have
been published [3], the most commonly used basic protocol for
hESC cardiac differentiation has a low efficiency of ,8–22% [6,7],
and takes up to 21 days to produce contracting areas. This protocol
performs even less efficiently for hiPSC (,1–25%) and take up to 30
days to generate contracting hEB [8,9].
Multiple approaches have been described for directed and
efficient cardiac differentiation of hESC. These methods include co-
culture with END2 (mouse visceral endoderm-like cell) stromal
layers [4,10,11], differentiation of hESC in monolayer culture with
high levels of activin A and bone morphogenetic protein 4 (BMP4)
which yielded .30% cardiomyocytes [12], and the formation of
human embryoid bodies (hEB) with growth factor supplementation
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18293resulting in 23–60% of hEB contracting [13,14,15] or suspension in
END2conditioned medium resultingin,12–70% hEBcontracting
[10,14]. These techniques are all limited in their capacities for scale-
up due to inherent low-throughput design, poor differentiation
yields, and the use of expensive reagents. Most importantly, there is
great inconsistency in differentiation efficiency between various
hESC lines. This variability is likely a function of genetic and
epigenetic differences between hESC lines [16,17,18] that directly
impact their cardiac differentiation capacity [19,20,21]. hiPSC lines
exhibit even broader epigenetic diversity [22] which may
additionally limit their cardiac differentiation capacity [8]. There-
fore, existing cardiac differentiation protocols developedusing select
hESC lines with propensities toward cardiac differentiation may not
be applicable to genetically and epigenetically diverse patient-
specific hiPSC lines. These limitations highlight the need for a
reproducible, fully optimized and universally applicable differenti-
ation system capable of overcoming the interline variability that
commonly exists amongst human pluripotent stem cells (hPSC). As
yet, no cardiac differentiation system optimized specifically for
hiPSC has been demonstrated. In addition to poor differentiation
yields, another limitation of hiPSC for cardiac drug testing, disease
modeling or cellular therapies involves the caveats associated with
generating hiPSC using retroviruses or lentiviruses. Despite overall
silencing of integrated retroviral and lentivector promoters during
hiPSC generation, low level expression of viral transgenes or vector
promotershasthepotentialforinsertionalmutagenesisormalignant
transformation following cardiac differentiation [23].
We hypothesized that undifferentiated hPSC growth rate, hEB
formation, media formulation, and exposure to growth factors
during cardiac differentiation could all be systematically optimized
to improve cardiac differentiation. We identified and rigorously
optimized .45 variables that affect the experimental variation of
cardiac differentiation in genetically diverse hPSC lines. We used
this data to develop a universal cardiac differentiation system that
has an average efficiency of 94.762.4% hEB contracting for a
diverse repertoire of hESC lines and hiPSC lines, including those
generated from fetal fibroblasts using lentiviral methods, or
neonatal CD34
+ cord blood cells and mature-donor dermal
fibroblasts using non-viral episomal-based methods.
Results
A systematic strategy for sequentially optimizing cardiac
differentiation
To improve the efficiency and reproducibility, and to reduce the
known interline variability of cardiac differentiation [15,20,21], we
analyzed existing cardiac differentiation strategies [6,12,13,14,
15,24], identified .45 possible experimental variables (Figure S1),
and initiated a strategy for systematically optimizing the cardiac
differentiation of hPSC. We employed our previously described
forced aggregation cardiac differentiation system, which efficiently
forms uniform homogeneous hEB from known numbers of cells
[15] (Figure S2A). For initial system development, we used the
hESC line H9 (WA09). We divided our cardiac differentiation
system into four distinct phases for rigorous, systemic optimization
(Figure 1A): phase 1, uniform undifferentiated hPSC growth;
phase 2, hEB formation/mesoderm induction; phase 3, hEB
cardiac specification; phase 4, contracting cardiomyocyte devel-
opment. We used a contracting hEB assay to sequentially assess
improvements in cardiac differentiation in each of these four
phases by counting the number of hEB contracting after nine days
of differentiation (Figure S2B). The final fully-developed system
(Figure 1A and Figure S2C) reproducibly formed homogeneous
H9 hEB (Figure 1B) which began contracting at a significantly
(p,3610
210) improved efficiency of 91.261.9% contracting hEB
in an accelerated time period of only 9 days of differentiation,
compared to an average efficiency of 10.466.8% contracting hEB
in 20 days using traditional methods (Figure 1D). Additionally, in
contrast to prior methodologies that produce only rare, focused
areas of contracting cells at the periphery of the hEB, our
optimized differentiation method produced robust and forceful
contractions within the entire hEB (Figure 1C and Movie S1).
Efficient generation of vector and transgene-free hiPSC
from CD34
+ cord blood and adult fibroblasts
To avoid potential clinical caveats of cardiomyocytes differen-
tiated from retroviral or lentiviral derived-hiPSC (e.g., insertional
mutagenesis), we generated several non-viral, transgene-free
hiPSC for cardiomyocyte differentiation using a three plasmid,
seven-factor (SOKMNLT; SOX2, OCT4 (POU5F1), KLF4, MYC,
NANOG, LIN28, and SV40L T antigen) EBNA-based episomal system
[25]. These hiPSC cell lines were generated from adult fibroblasts
(iPSCWT2, iPSCWT4), and CD34
+ cord blood cells (CBiPSC6.2,
CBiPSC6.11, CBiPSC6.13, and CBiPSC19.11). hiPSC lines
expressed high levels of pluripotency markers by immunocyto-
chemistry (Figure 2A) and real-time qRT-PCR (Figure 2C), and
formed trilineage teratomas when injected into murine recipients
(Figure 2B). Lack of genomic episomal vector or transgene
integration and expression was demonstrated by Southern blot,
genomic PCR, and RT-PCR studies of plasmid backbone and
transgene sequences (Figure 2D–E). All non-viral hiPSC evaluated
in these studies expressed similar levels of pluripotency markers,
formed similar teratomas, and were demonstrated to be transgene-
and vector-free. Full details of the derivation and characterization
of these non-viral hiPSC are described in Methods. In comparison
to episomal reprogramming of adult fibroblasts [25], CBiPSC
from plasmid-nucleofected CD34
+ cord blood cells emerged
rapidly in 14–21 days at extremely high frequencies (average
1.4% efficiency; e.g. 300–1450 alkaline phosphatase
+ TRA-1-81
+
colonies per million CD34
+ input cells; range 0.4%–3.6%
efficiency; n=5). These efficiencies were comparable to previously
reported ‘high efficiency’ non-integrating reprogramming systems
using either the same EBNA1-based episomal plasmid system we
used (0.1–1% efficiency, [26]), or alternatively, synthetic mRNA-
based reprogramming protocols (0.6–4.4% efficiency, [27]). Below
we describe our approach for the systematic optimization of each
of the four phases of our highly efficient cardiac differentiation
system in various hPSC lines.
Phase 1: Defined single-cell culture promotes uniform
growth of hPSC lines
We first hypothesized that promoting uniform growth of
undifferentiated hPSC lines is critical for subsequent reproducible
differentiation and for the derivation of a universal cardiac
differentiation system. To conform all hPSC lines to one universal
culture method, we adapted all lines to feeder-free monolayer
growth [28] on the basement membrane matrix Geltrex in
conditioned medium [29]. In this system, cells were enzymatically-
passaged to single cells on a rigid timescale of every three days,
counted using an automated cell counter, and plated at fixed cell
densities (Figure 3A). This approach resulted in controlled,
reproducible growth of four hESC lines (H1, H9, ES03, and SI-
233), as well as seven hiPSC lines including lentiviral fetal lung
fibroblast-derived hiPSC lines iPS(IMR90)-1 and iPS(IMR90)-4,
as well as our own episomal CD34
+ cord blood-derived hiPSC
lines (CBiPSC6.2, CBiPSC6.11 and CBiPSC6.13) and non-viral
adult dermal fibroblast-derived lines (iPSCWT2 and iPSCWT4)
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maintained high expression levels (.99%) of pluripotency markers
SSEA4 and TRA-1-60 (Figure 3C).
Phase 2 (d0–d2): A chemically defined medium
supplemented with BMP4 and FGF2 accelerates
mesoderm induction
To accelerate mesoderm induction in the second phase of this
system, we optimized hEB formation via forced aggregation [15] by
systematically testing 21 published hESC and mESC differentiation
and pluripotent culture media formulations. We found that the
chemically defined media formulation originally devised by Wiles
and Johansson [30] formed the most reproducibly homogeneous
hEB via forced aggregation (Figure S3A). By subtraction analysis
we found that only three of the components of this media (basal
media, PVA, and insulin) were necessary for forced aggregation
hEB formation (Figure S3B). We next tested the individual
supplements to this media formulation in an effort to further
enhance cardiac differentiation. The final d0–d2 media formu-
lation that gave the most efficient cardiac differentiation is
Figure 1. Systematic optimization of cardiac differentiation of human pluripotent stem cells. (A) Schematic of the optimized cardiac
differentiation system demonstrating: Phase 1, uniform growth of hESC/hiPSC as monolayers. Phase 2 (d0–d2), aggregation of 5000 single cell hESC
or hiPSC in chemically defined RPMI+PVA medium in V96 plates. Phase 3 (d2–d4), cardiac specification using FBS or hSA containing medium. Phase 4
(d4+), cardiac development, hEB are allowed to adhere to U96 tissue culture treated plates in RPMI+INS. (B) Typical d2 hEB formed using the forced
aggregation procedure in RPMI-PVA to demonstrate homogeneity in hEB size. Scale bar=500 mm. (C) Typical d9 contracting hEB formed using the
optimized cardiac differentiation method with the contracting area circled, note minimal fibroblast outgrowth. Scale bar=200 mm. (D) Efficiency of
generation of contracting hEB produced in this system (New system, n=48), with comparisons to xeno- and serum-free conditions (Xeno-/serum-free,
n=5), our previous method (Previous system, n=7), and typically used methods (Typical, n=9). Error bars, 6 S.E.M.
doi:10.1371/journal.pone.0018293.g001
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+ cord blood progenitors. (A) Representative immunocytochemistry of pluripotency
markers POU5F1 (OCT4), NANOG, TRA-1-81, and SSEA4 in hiPSC line CBiPSC6.2 after .20 passages. (B) Representative hematoxylin and eosin staining of
teratoma sections derived from CBiPSC6.2 after .20 passages demonstrating ectodermal, endodermal and mesodermal lineage differentiation. All
CBiPSCclonesinthesestudies formedsimilar teratomas.(C) Real-timeRT-PCR studies p15 CBiPSClines forendogenouspluripotencygenes usingprimers
that distinguish endogenous expression from transgenes (see Methods). (D) The presence of plasmid transgene sequences examined by PCR at p11 in
CBiPSC6.2, CBiPSC6.11, CBiPSC6.13, CBiPSC19.11 (lanes 3–6, respectively) and negative control H9 hESC (p48) (lane 1) compared to positive control early
culturesfromp2(lane 2). RT-PCRanalysisofselectedplasmidsequences inp11 CBiPSC6.2, CBiPSC6.11,CBiPSC6.13, CBiPSC19.11(lanes 8–11, respectively)
and negative control H9 hESC (lane 7) and p2 cultures (lane 12). (E) Genomic Southern blot analysis for episomal vector backbone integration in lines
CBiPSC6.2, CBiPSC6.11, CBiPSC6.13, CBiPSC19.11 (p15) (lanes 2–5, respectively), H9 hESC (p55) (lane 1). Combination 6 episomal vector DNA was diluted
as positivecontrol to the equivalents of 0.4 and 4 integrations per haploidgenome (0.46and 46). L:1 kbplus ladder. Thesestudies were alsoconducted
for non-viral adult fibroblast-derived hiPSC lines iPSCWT2 and iPSCWT4 with similar results (Machairaki et al.,i np r e p a r a t i o n ) .
doi:10.1371/journal.pone.0018293.g002
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growth factors BMP4 and FGF2 was determined to be necessary
for optimally efficient cardiac differentiation (Figure S4A, B).
Other growth factors including NODAL, activin A, TDGF1,
BMP2, BMP6, TGFB, IGF1, IGF2 and WNT3A were each
individually titrated between 1–100 ng mL
21, and none were
Figure 3. Controlled growth of hPSC lines for reproducible cardiac differentiation. (A) Schematic of monolayer hESC/hiPSC culture
technique. This monolayer technique uses conditioned medium prepared in a defined manner, single-cell passaging, automated cell counting,
plating cells at a known density, and passaging every three days. (B) Stable growth rates of H9 hESC, viral fetal fibroblast-derived hiPSC lines
iPS(IMR90)-1 and iPS(IMR90)-4, non-viral CD34
+ cord blood-derived hiPSC lines CBiPSC6.2, CBiPSC6.11, and non-viral adult fibroblast-derived hiPSC
line iPSCWT4. (C) The homogenous culture phenotype seen when culturing H9 hESC as feeder-free monolayers (left), compared in comparison to
typical colony morphology of cells grown in co-culture with MEF (right). (D) Comparable SSEA4 and TRA-1-60 expression of H9 hESC growing as
monolayer cultures (left) or colonies grown in co-culture with MEF (right).
doi:10.1371/journal.pone.0018293.g003
Table 1. Final optimized media formulations for each of the three steps of cardiac differentiation.
Phase 2 (d0–d2) medium RPMI-PVA Phase 3 (d2–d4) medium RPMI-FBS Phase 4 (d4+) medium RPMI-INS
RPMI 1640 RPMI 1640 RPMI 1640
400 mM 1-thioglycerol 400 mM 1-thioglycerol 400 mM 1-thioglycerol
4m gm L
21 PVA 20% FBS or human serum 10 mgm L
21 hr-Insulin
10 mgm L
21 hr-Insulin Xeno-/serum-free variant 16chemically defined lipids
25 ng mL
21 BMP4 RPMI 1640
5n gm L
21 FGF2 400 mM 1-thioglycerol
16chemically defined lipids 16chemically defined lipids
1 mM Y-27632 5 mg mL
21 HSA
5% O2 280 mM L-ascorbic acid
The basal medium RPMI 1640 was found to be most successful for cardiac induction during phase 2 and phase 3 and therefore was maintained for phase 4. The addition
of the thiol 1-thioglycerol was found to be essential for hEB formation and survival. High concentrations of PVA enhanced hiPSC hEB formation. Insulin was essential for
hEB formation. The combination of BMP4 and FGF2 was optimal for mesoderm specification whilst FBS or human serum was essential in phase 3 for ,90% contracting
hEB differentiation efficiency. The addition of lipids in phase 2 and 4 enhanced hEB survival. A low concentration of Y27632 (ROCK inhibitor) enhancedt h e
reproducibility of hEB formation. The xeno-/serum-free variant of the phase 3 medium required the addition of HSA and L-ascorbic acid to maintain cardiac
differentiation and produces ,60% of hEB contracting by d15 of differentiation.
doi:10.1371/journal.pone.0018293.t001
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also assessed the effects of cell handling prior to and during forced
aggregation. Cardiac differentiation of hEB made from mono-
layers of pluripotent cells passaged one day prior to aggregation
was more efficient (93.863.3% contracting hEB) than the
differentiation of those passaged 2 days (46.964.1%), or 3 days
(26.068.0%) earlier (Figure S5H). Centrifugal force was not
required for hEB formation using this media formulation (Figure
S5F). Other aggregation hEB formation techniques such as
AggreWell (StemCell Technologies) [31] or ‘Shrinky-dink’
methods did not result in cardiac differentiation [32] (data not
shown).
Phase 3 (d2–d4): Efficient cardiac specification is
inhibited by insulin and potentiated by FBS or human
serum
Once H9 hEB formation and mesodermal induction was
reproducibly maximized, we focused on optimizing the third
phase of differentiation: cardiac specification. We found that
supplementation with 20% FBS was essential for efficient cardiac
differentiation (Figure S6A) and that the supplier of FBS did not
impact cardiac differentiation (Figure S6B). Additionally we found
that replacement of FBS with human serum maintained this same
high efficiency differentiation. Finally, we discovered that the
supplementation of this d2–d4 step with any level of insulin (which
was essential for the preceding phase 2 d0–d2 hEB formation step)
completely abrogated cardiac specification (Figure S6H).
Phase 4 (d4+): hEB adherence and chemically defined
media enhances final cardiomyocyte differentiation
Once we completed formulation of the optimal cardiac
specification media, we focused on enhancing the final steps of
cardiomyocyte differentiation and maintenance. We found that
adherence onto tissue culture treated plates on d4 enhanced
subsequent cardiomyocyte development, whilst adherence before
this time-point almost completely ablated contraction (Figure
S5D). Unlike the third phase media formulation, the media
formulation for this fourth phase was not dependent on factors
contained in FBS (Figure S7A). Moreover, once contraction had
begun, we found that hEB could be successfully maintained in a
variety of media (e.g. RPMI+FBS or RPMI+PVA or simple
RPMI+INS (Table 1)) for at least 3 months with continuous
contraction. In both RPMI+PVA and RPMI+INS media the hEB
formed substantially less fibroblast outgrowth than seen when
using RPMI-FBS. A summary of the optimal media and factors for
each phase is provided in Table S2.
Polyvinyl alcohol (PVA) and physiological oxygen tension
synergize to induce highly efficient cardiac
differentiation of hiPSC
We next assessed the performance of our H9 hESC-optimized
cardiac differentiation system, using the hESC lines H1, ES03
and SI-233, and we found that similarly high efficiencies of
cardiac differentiation could be achieved. However, this system
produced only low levels (2.5–20.5%) of contracting hEB for
various hiPSC lines (Figure 4A, C). Attempts to re-optimize the
dose-response dependant variables from phases two and three
using the hiPSC line iPS(IMR90)-1 resulted in identical optimal
conditions to those we had found for H9, albeit at lower
efficiencies. We noted that the main impediment to efficient
hiPSC differentiation was that hiPSC-derived hEB were substan-
tially less stable and robust than those formed from hESC lines.
To improve this hEB instability we tested the inclusion of
extracellular matrix proteins (1:100 Matrigel or laminin-511 and
nidogen-1) [33] during hEB formation (at d0–d2, d2–d4 or d0–
d4), but we found that these proteins completely abrogated
cardiac differentiation (data not shown). However, the inclusion
of increasing concentrations of the synthetic polymer polyvinyl
alcohol (PVA; from 1 mg mL
21 to 4 mg mL
21) was highly
effective in increasing the percentage contraction of iPS(IMR90)-
1 hiPSC hEB from 20.663.7% to 68.362.3%, and CBiPSC6.2
hEB from 2.561.8% to 34.2610.2% (Figure 4B). Concentrations
of PVA above 4 mg mL
21 were less effective at improving
cardiac differentiation (Figure S4K). This increased PVA
concentration did not affect hESC experiments that already
consistently differentiated at high (.91.4%) efficiencies at 1, 2, or
4m gm L
21 (Figure 3A). We also assessed the effects of
physiological oxygen tensions on differentiation efficiency by
subjecting differentiation cultures to 5% O2 at timed intervals (i.e.
during d0–d2, d2–d4, d4 onwards, or combinations thereof).
These experiments revealed that 5% O2 between d0–d2
significantly (p,0.028) enhanced the differentiation of all hiPSC
lines tested but had little effect on the already high efficiency of
hESC differentiation (Figure 4B, C). The combined use of higher
concentrations of PVA and timed exposure to physiological
oxygen tensions significantly (p,0.04) enhanced cardiac differ-
entiation and allowed each of the seven hiPSC lines we tested to
achieve cardiac differentiation with an average efficiency
94.762.4% of hEB contracting (Figure 4C and Movie S2).
hPSC-derived cardiomyocytes display functional cardiac
properties including reproducible electrophysiological
profiles and drug responsiveness
Using real-time RT-PCR analysis, we established that hEB
differentiated using this optimized system progress through the
normal developmental stages of cardiac lineage gene expression
(Figure 5A). Our data demonstrated that, compared to our
previous system [15], the relative peak in mesodermal gene
expression (assayed by expression of T (Brachyury) and MESP1)
was substantially increased (2–6-fold) and accelerated from 4 to 2
days. Expression of cardiac progenitor markers (NKX2-5 and
ISL1) and terminal cardiac markers (TNNT2 and MYH6)w a s
substantially enhanced (5–2500-fold) (Figure 5A). We also
analyzed the expression of the cardiac structural proteins a-
actinin (ACTN2) and cardiac troponin I (TNNI3) using
immunocytochemistry, and we showed that cardiomyocytes
differentiated from H9 hESC and CBiPSC6.2 formed striated
sarcomeres (Figure 5B, C). Gap junction formation was also
demonstrated by expression of CX43 (GJA1; data not shown).
Finally, intracytoplasmic staining and flow cytometry analysis of
various hESC and hiPSC lines demonstrated that the entire
contents of each 96-well consisted of 64–89% cardiac troponin I
(TNNI3)
+ cardiomyocytes (Figure 6).
Using optical mapping methods, we next evaluated the
electrophysiological properties of cardiomyocytes generated from
H9 hESC with this system. The hEB were either mechanically
dissected for micromapping or dissociated into single cells and
plated as a confluent monolayer for macromapping [34]. hEB and
monolayers were then stained with either voltage- or calcium-
sensitive dye and optically mapped to visualize spontaneous
activity and response to electrical field stimulation (Figure 7A, 8A,
S8). Replicates of voltage micromapping experiments (n=19)
demonstrated reproducible action potential duration and conduc-
tion velocities (Figure 7B and Movie S3). Optical mapping of
intracellular calcium demonstrated a physiological calcium
transient (Figure 7B, 8B, S8 and Movie S4). To assess cardioactive
drug responsiveness, 20 mM isoproterenol or 100 mM pinacidil
Highly Efficient Cardiac Differentiation of hiPSC
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adrenergic stimulation response and the presence of functional
KATP channels, respectively. Both drugs produced a shortening of
the action potential (Figure 7C and Figure S8A). 20 mM
isoproterenol was demonstrated to induce increase in conduction
velocity in CBiPSC6.2 hEB (Figure 8B). Functional electrical
coupling within a cardiomyocyte monolayer (Figure S8A) and
between a pair of hEB (Figure S8B) was demonstrated by voltage
mapping. Contracting hEB derived from the hiPSC lines
CBiPSC6.2 (Figure 8) and iPSCWT2 (data not shown) were also
tested in the same manner and yielded similar results.
Cardiac differentiation can be performed using xeno-free
and serum-free conditions
To further maximize the ultimate clinical utility of our method,
we also conducted parallel optimization experiments that focused
on the complete elimination of serum during the third phase of
differentiation (d2–d4). We formulated a serum-free optimal
media containing human serum albumin (HSA), L-ascorbic acid,
and lipids (Table 1 and Figure S9) and found that this formula,
used from day 2–4 to replace the FBS or human serum containing
media produced 64.863.3% of hEB contracting by d15 of
differentiation (Figure 1D). Additional supplementation with
Figure 4. PVA supplementation and staged exposure to physiological oxygen eliminates interline variability of cardiac
differentiation. (A) Increasing the concentration of PVA from 1 mg mL
21 to 4 mg mL
21 PVA in the d0–d2 media formulation enhanced the
differentiation of viral fibroblast-derived hiPSC line iPS(IMR90)-1, and non-viral cord blood-derived hiPSC line CB-iPSC6.2, whilst not affecting H9 hESC
(n=3). (B) Exposure of iPS(IMR90)-1 hEB to physiological (5%) oxygen tensions from differentiation d0–d2 also enhanced cardiac differentiation (n=3,
p,0.005). Identical conditions did not improve already highly efficient H9 hESC differentiation. (C) Combining both physiological oxygen tension and
4m gm L
21 PVA between d0–d2 eliminated interline differentiation variability in hiPSC derived using both viral- and non-viral-techniques (n$3,
p,0.005). Error bars, 6 S.E.M.
doi:10.1371/journal.pone.0018293.g004
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ation (data not shown).
Discussion
We have demonstrated that by systematically and rigorously
optimizing culture conditions, we could significantly improve
cardiac differentiation efficiency to an average of 94.762.4% of
hEB contracting from four hESC and seven hiPSC lines. The
variation in cardiac differentiation potential among different hPSC
lines cultured under similar conditions has been well documented
[15,20,21,35]. Although robust cardiac differentiation in select
hPSC lines has been reported [9,12,13,24], highly efficient cardiac
differentiation of multiple independently derived hESC and hiPSC
lines using a single technique has thus far not been possible. One
reason for this difficulty may be that significant variability exists in
the innate response to cardiac inductive factors among different
hESC lines [8,15,20,35]. Previous cardiac differentiation systems
may simply leverage the innate cardiac potential of specific hESC
lines, and therefore not be suitable for other hESC lines with
differing propensities. Such cardiac differentiation systems may be
even less effective for hiPSC differentiation, as these cell types have
Figure 5. Characterization of hPSC cardiomyocyte differentiation. (A) Comparison of real-time RT-PCR for markers of mesoderm (T, MESP1),
cardiac progenitors (NKX2.5, ISL1), and cardiomyocytes (TNNT2, MYH6) during hESC differentiation using either the Previous system or New system.
Analysis was performed using the
DDCt method with relative expression calculated using d0 of differentiation (hESC samples) as baseline. 18S RNA
expression was used for normalization. Primers are shown in Table S1. (B) Immunocytochemistry for cardiac markers in hEB differentiated from H9
hESC. Troponin I (red), a-actinin (green) and DAPI (blue) at low power (top panels) demonstrating unaligned striations throughout the hEB and higher
power (lower panels) demonstrating area of aligned striation. (C) Immunocytochemistry for cardiac markers in hEB differentiated from CBiPSC6.2.
doi:10.1371/journal.pone.0018293.g005
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[36].
In developing a universal cardiac differentiation system, we
evaluated and tested the strengths of multiple published protocols
with a multivariate strategy. Although we initially favored a
monolayer differentiation based technique [12] due to its
simplicity and reproducibility, monolayer based differentiation
systems have been demonstrated to be less responsive to cardiac
inductive factors than in hEB systems [37]. Our previous data
demonstrated that hEB could be formed from feeder-free single-
cell hESC using forced aggregation in chemically defined media
(CDM) [30]. The use of CDM enhanced the effectiveness of
recombinant growth factors due to the exclusion of FBS or BSA
[38]. We tested a large number of mesodermal morphogens from
the NODAL, BMP4, and WNT signaling cascades for cardiogenic
potential. However, only the combination of BMP4 and FGF2 was
suitable for highly efficient cardiac differentiation. Indeed, BMP4
is a known potent mesoderm morphogen in hESC [39], with a
brief temporal window of effectiveness for mesendoderm induction
(d1–d2) [40]. Furthermore, BMP4 and FGF2 synergize to promote
mesoderm induction [39,41]. We noted that in the d2–d4 stage,
insulin completely ablated cardiac differentiation even at
5 mgm L
21. The negative effect of insulin on cardiac differenti-
ation has been previously reported with an effective window from
d3 onwards [14]. Freud et al. demonstrated that insulin, acting
primarily via IGF1R and PI3K/Akt, has an inhibitory effect on
each of d0–d5 of cardiac differentiation, due to a redirection of
cardiogenic mesoderm to neuroectoderm [10]. We have defined
this negative effect to a small temporal window of d2–d4. One
reason for the lack of negative effect of insulin in our system
between d0–d2 is that it was required during this period for
successful hEB formation (Figure S3B). We also discovered that
either 20% FBS or human serum was essential for phase 3 (d2–d4)
of this system, indicating that additional serum factors are required
at this stage. This requirement of FBS for cardiac differentiation
has previously been demonstrated [42]. Although FBS is
undefined, the 20% FBS media contains approximately 0.2–
20 mgm L
21 of insulin [43], suggesting that cardiac differentiation
efficiency may be further enhanced if the cardiogenic properties of
FBS can be identified and recreated in the absence of insulin. In
our defined serum- and xeno-free version of our differentiation
system (Table 1 and Figure S9), replacing FBS/human serum with
HSA, lipids and L-ascorbic acid [11] reduced differentiation
efficiency to ,65%, suggesting that additional factors in FBS/
human serum are required at this stage. After day 4 of
differentiation, we found that only a very simple media was
required for the completion of cardiomyocyte specification,
suggesting that once the cardiomyocyte program is initiated by
sequential treatment with BMP4/FG2 followed by FBS, this final
process is essentially self-specifying. Once contraction began, hEB
could be maintained in a simple media formulation for extended
periods, as previously described [44].
Figure 6. Intracytoplasmic flow cytometry analysis of cardiomyocyte marker expression. Expression of cardiac troponin I in contracting
hEB from differentiated H9 hESC, ES03 hESC, viral fibroblast-derived line iPS(IMR90)-1 hiPSC, and non-viral CD34+ cord blood-derived hiPSC lines
CBiPSC6.2 and CBiPSC6.11. For each sample the entire U-well contents of one 96-well plate was enzymatically digested into a single cell suspension
and analyzed by flow cytometry.
doi:10.1371/journal.pone.0018293.g006
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hESC was established, we found that our improved system
overcame the well-documented variation in cardiac differentia-
tion potential among different hESC lines [15,20,21,35]. We then
further applied this system to hiPSC cardiac differentiation, and
noted that efficiency was initially poorer than that of hESC, as
reported in other differentiation systems [8], and would require
additional optimizations. These results were consistent with the
notion that there are important biological differences between
hiPSC and hESC. For example, it has been demonstrated that
early passage iPSC retain an epigenetic memory of their somatic
cell of origin which may affect lineage-specific differentiation
capacity [22,45]. Such inherent epigenetic limitations of iPSC
lineage-specific differentiation have been partially overcome by
the use of chromatin-modifying drugs (e.g. the demethylation
inhibitor 5-azacytidine [9,22] or the HDAC inhibitor trichostatin
A [46]). In contrast, superior hiPSC cardiac differentiation
efficiencies were achieved in our system without need for non-
specific, toxic, and potentially mutagenic drugs. Instead, we
achieved comparably high efficiencies in both hESC and hiPSC
by applying our highly efficient hESC system with enhancement
of the structural integrity of hiPSC hEB using PVA, and using
Figure 7. Electrophysiological characterization H9 hESC contracting hEB using optical mapping. (A) Voltage micromapping. a, Phase
contrast image of H9 hEB at 46magnification. b, Voltage activation map (arrows indicate direction of electrical wave propagating across hEB). c,
Action potential duration (APD) map. d, Representative transmembrane potential (Vm) trace at position denoted by the small square in a and b during
0.5 Hz field stimulation. e, Mean APD and conduction velocity (CV) measurements from 19 hEB (error bars represent 6 s.d.). Coefficient of variation
(COV, population s.d. divided by mean) for APD was 0.30 and for CV was 0.88 across hEB population. COV within an individual hEB was calculated
from multiple APD measurements across all of the recording sites for that hEB (panel A, c) and was 0.04260.030 (s.d.) when averaged across 19 hEB.
(B) Intracellular calcium micromapping. a, Phase map of hEB at 66magnification. b, Calcium map (arrows indicate direction of propagating calcium
wave). c, Representative intracellular calcium (Cai) trace at position denoted by the box in a and b. (C) The beta-adrenergic agonist isoproterenol
shortened the mean APD in all 4 hEB by an average of 2368 ms (mean 6 s.d.). * indicates p<0.01 in a paired Student’s t-test.
doi:10.1371/journal.pone.0018293.g007
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common constituent of embryo culture media, is a cost-effective
media additive that is used to replace the need for BSA or FBS,
creating a true chemically defined media, as well as functioning as
an adhesive. The adhesive properties of PVA likely enhance
hiPSC hEB formation, and promoted their subsequent cardiac
specification. Low oxygen tensions also have established effects
for improving embryoid body formation [47,48]. Low oxygen
tensions also affect a wide range of developmental processes,
including cardiogenesis, the stem cell niche, and modulation of
NODAL, VEGF, WNT and NOTCH signaling [49]. In
particular 5% O2 has been shown to induce WNT pathway
signaling by enhancing b-catenin activation [49]. The positive
effect of 5% O2 during only d0–d4 of our differentiation, and
subsequent negative effect after day 4 suggests that WNT
signaling may be the 5% O2 effector in our system. We found
that the addition of the WNT signaling inhibitor DKK1 only
impacted cardiac differentiation when added at d0–d2 and none
of the subsequent stages (data not shown).
Electrophysiological assessment of our contracting hEB dem-
onstrated that these hEB displayed characteristics of immature
cardiomycytes. Although our electrophysiology method does not
evaluate single or clusters of cells, the whole hEBs that were
assessed displayed, on average, a ventricular-type electrophysio-
logical profile. In addition, we demonstrated that each well
contained a high percentage of troponin I
+ cells. Based on this
data for every 500,000 input cells, one 96-well plate produced
,500,000 cells, and an average of 407,000 cardiomyocytes.
In summary, this system produced highly efficient cardiomyo-
cyte differentiation from a wide variety of independently derived
hESC and nonviral, non-integrated hiPSC lines. Importantly we
demonstrate that the contracting cells produced using this system
expressed normal cardiomyocyte markers, were capable of
electrically coupling, and displayed highly reproducible electro-
physiological profiles. The development of a universal cardiac
differentiation protocol that can translate across multiple plurip-
otent stem cell lines allows immediate application to genetically
diverse hiPSC lines created from patients with cardiac related
diseases (e.g. long QT syndrome [50,51]). The uniformity of the
electrophysiological profiles of these cells highlights the potential
for translation of this methodology to future high-throughput
cardiotoxicity testing and novel drug discovery assays that can be
used at various stages of drug development. The generation of
cardiomyocytes from clinically safe cord blood-derived hiPSC is
especially attractive since this cell source is widely available, carries
relatively few somatic mutations, and could ultimately be used to
create an HLA-defined stem cell bank for hiPSC generation via
worldwide networks of existing cord blood banks. Overall, the
development of this efficient cardiac differentiation system should
greatly facilitate the utility of hiPSC-derived cardiomyocytes in
drug development and cardiotoxicity screening, cardiac develop-
mental biology and disease modeling, and contribute to the future
Figure 8. Electrophysiological characterization non-viral cord blood-derived hiPSC contracting hEB differentiated using optical
mapping. (A) Voltage micromapping. Phase image of CBiPSC6.2 hEB at 46magnification. b. Voltage map, hEB were stained with di-4-ANEPPS (a
voltage-sensitive fluorescent dye), and electrically field-stimulated at the same pacing rate (arrows indicate direction of electrical wave propagating
across hEB). c. Action potentials during 0.5 Hz field stimulation. d. Average conduction velocity (CV) measurements (mean 6 standard deviation) for
control and 15 min after addition of 50 mM isoproterenol during 0.5 Hz field stimulation. (B) Calcium micromapping. a. Phase image of beating hEB.
b. Calcium map (arrows indicate direction of calcium wave propagating across beating hEB). c. Representative calcium transient (Ca) waveforms
during 0.5 Hz field stimulation. Box in a and b denote site of recording in c.
doi:10.1371/journal.pone.0018293.g008
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medicine.
Materials and Methods
Human pluripotent stem cell culture
All tissue culture reagents were purchased from Invitrogen
(Carlsbad, CA, http://www.invitrogen.com) unless otherwise stated.
MEF, hESC and hiPSC cultures were maintained at 37uC, 5% CO2
and 85% relative humidity. Medium was changed every day on
hESC and hiPSC cultures. Physiological (5%) oxygen conditions
were created in a hypoxia chamber using nitrogen gas by ProOx
Oxygen and ProCO2 CO2 controllers (BioSpherix, Lacona, NY,
http://www.biospherix.com). hESC lines H1 (WA01) and H9
(WA09) [52], ES03 (HES1) [53], and hiPSC lines iPS(IMR90)-1-
DL-1 and iPS(IMR90)-4-DL-1 derived from fibroblasts using
lentiviruses [25] were obtained from the WiCell WISC Bank
(Madison, WI, http://www.wicell.org). The hESC line SI-233 [54]
was obtained from Stemride International (London, UK, http://
www.stemride.com). hiPSC lines CBiPSC6.2, CBiPSC6.11, and
CBiPSC6.13 were derived inourlab from CD34
+ cord blood using a
modified episomal plasmid methodology described below. hiPSC
lines iPSCWT2, and iPSCWT4 were derived in our lab from adult
fibroblastsusingamodified episomalplasmid methodologydescribed
below. All hESC lines used in these studies were approved for use by
The Johns Hopkins University Institutional Stem Cell Research
Oversight Committee. Pluripotent stem cell lines were initially
cultured as colonies on irradiated (5000 cGy) MEF (E13.5 DR4
seeded at 2610
4 cells cm
22)i n6 - w e l lp l a t e s( G r e i n e rB i o - O n e )i n
hESC medium consisting of DMEM-F12, 15% Knockout Serum
Replacer (KSR), 1% non-essential amino acids (NEAA), 100 mM2 -
mercaptoethanol and 4 ng mL
21 human FGF2 (R&D Systems,
Minneapolis, MN, http://www.rndsystems.com) and passaged with
collagenase IV. For transfer of hiPSC and hESC to monolayer
culture [28] 1 confluent well of a 6-well plate was treated with
TrypLE Select and single cells were passaged into a T25 flask (BD
Biosciences, Bedford, MA, http://www.bdbiosciences.com) coated
with a 1:400 dilution (200 mLc m
22) of Geltrex in 5 mL of
conditioned medium. Conditioned medium was made essentially as
previouslydescribed[29].Inbrief,confluentp2 MEFwere irradiated
(5000 cGy) and seeded at 6610
4 cells cm
22 on gelatin coated flasks
in MEF medium consisting of DMEM (with Glutamine), 10% fetal
bovine serum (FBS, Characterized, Hyclone, Thermo Fisher,
Waltham MA, http://www.hyclone.com), 1% NEAA, 55 mM2 -
mercaptoethanol. After allowing MEF to attach for 24 h cells were
washed and media was replaced with 0.5 mL cm
22 hESC medium.
Medium was conditioned for 22–26 h, pooled, filter sterilized and
supplemented with an additional 4 ng mL
21 FGF2 and stored at
220uC. Conditioned medium was collected for 7 days. Confluent
cultures were passaged every 3 days washing with PBS then treating
with room temperature TrypLE Select for 1 min at 37uC. Confluent
cultures were passaged every 3 days with TrypLE Select. Cells were
counted with a Countess Automated Cell Counter and seeded at
1.25610
6 cells per T25 flask. All hPSC lines commonly grew from
1.25610
6 to 5610
6 in these 3 days.
Generation of Vector and Transgene-Free hiPSC
EBNA-based pCEP4 vectors pEP4 EO2S EN2L (OCT4, SOX2,
NANOG, LIN28), pEP4 EO2S ET2K (OCT4, SOX2, SV40LT,
KLF4), pEP4 EO2S EM2K (OCT4, SOX2, MYC, KLF4) were
obtained from Addgene (Cambridge, MA, http://www.addgene.
org). E. coli containing the plasmids were propagated and purified
using a Plasmid Maxi Kit (QIAGEN, Valencia, CA, http://www.
qiagen.com). Ratios of (1:1:1) were mixed as the seven-factor
SOKMNLT (Combination 6 [25]) and co-concentrated using a
QIAquick PCR Purification Kit.
For generation of the hiPSC lines iPSCWT2 and iPSCWT4,
adult fibroblasts from a normal 56 year-old female donor were
obtained from the Coriell Cell Repository (Coriell, Camden, NJ,
http://www.ccr.coriell.org/) and cultured in standard conditions.
Two-three days following passage, cells were trypisinized and
1610
6 cells were nucleofected in NHDF nucleofector solution
(VPD-1001, Lonza, Walkersville, MD, http://www.lonzabio.com)
with 6 mg total of the three plasmids using an AMAXA II
nucleofector (Lonza) and program U023. Cells were then plated
on three 10 cm plates seeded with irradiated MEF (5000 cGy,
E13.5 DR4 MEF seeded at 2610
4 cells cm
22) in fibroblast (MEF)
medium. Nucleofection solution medium was changed after 4–
6 hours. After 3 days fibroblast medium was replaced with hESC
medium containing 40 ng mL
21 FGF2. Medium was changed
every 2 days. Starting on Day 10 medium was changed every day
using MEF-conditioned medium (made as above) supplemented
with 40 ng mL
21 FGF2. After 21 days+ colonies were passaged
onto fresh irradiated MEF layers, and ESC-like colonies that
emerged were manually picked and expanded for further analysis,
as described [55].
For generation of the non-viral CD34+ cord blood-derived
hiPSC lines (CBiPSC6.2, CBiPSC6.11, CBiPSC6.13 and
CBiPSC19.11), 0.5–1610
6 human CD34
+ cord blood cells
(AllCells, Emeryville, CA, http://www.allcells.com) were expanded
in StemSpan-SFEM (StemCell Technologies, Vancouver, BC,
http://www.stemcell.com), supplemented with FTK (100 ng mL
21
FLT3L,10 ng mL
21 TPO and 100 ng mL
21 KITLG (SCF) (R&D
Systems)) in 1 well of a 12-well plate for 3 days. All reprogramming
culture steps were conductedintissueculture platesthat weretightly
wrapped in Saran wrap. After three days, 0.5610
6 cells were
nucleofected with 6 mg total plasmid DNA as above using CD34
+
nucleofector solution (VPA-1003, Lonza) and program U-008. Cells
were incubated in RPMI/10% FBS for 4–6 hr then, washed in
SFEM and re-plated onto 6 wells of a Retronectin (Takara Bio,
Madison, WI, http://www.takara-bio.com)-coated (10 mgm L
21)
6-wellplateseededwithirradiated (2000 cGy)humanmesenchymal
stem cells (hMSC, AllCells, seeded at 2610
4 cells cm
22)i n
SFEM+FTK. On Day 3, cells were harvested (300 g, 5 min), and
re-plated onto irradiated MEF in SFEM+FTK, as above. On Day
4, two mL of hESC medium containing 40 ng mL
21 FGF2 was
added to CD34
+/MEF co-cultures. On Day 6, and every 2 days
thereafter, half of the medium in each well was removed, cells were
collected by centrifugation and media was aspirated and replace
with fresh media and returned to the wells. Starting on Day 10,
medium was changed every day using MEF conditioned medium
supplemented with 40 ng mL
21 FGF2. ESC-like colonies were
visible under these conditions and emerged as early as 7–21 days
post-nucleofection, and manually picked for expansion and further
characterization.
Pluripotency marker and teratoma assays
Whole hiPSC colonies were washed in PBS and fixed cold 3.7%
PFA in PBS, washed twice in PBS and permeabilized with 0.2%
Triton-X (Sigma) in TBS for 10 min where appropriate. Cells
were then incubated with 10% goat or donkey serum (Sigma) in
PBS for 1 hr at RT and incubated overnight at 4uC with anti-
human NANOG (1:500, goat IgG1, AF1997, R&D systems,), anti-
human POU5F1 (OCT4, 1:200, mouse IgG1), anti-human
SSEA4 (1:200, mouse IgG1,) (BD Biosciences) anti-human TRA-
1-60 (1:200, mouse IgM, Millipore) diluted in antibody diluent
(Invitrogen). Cells were washed 3 times in TBS-T then incubated
for 45 min at RT in the dark with secondary antibodies Cy3-
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Research, West Grove, PA), Alexa Fluor 488-conjugated goat anti-
mouse IgG1 (1:500, Invitrogen), or Alexa Fluor 488-conjugated
goat anti-mouse IgM (1:500, Invitrogen), which were diluted in
antibody diluent (Invitrogen). Cells were then washed 3 times in
TBS-T and mounted with ProLong Gold with DAPI (Invitrogen)
onto Superfrost Plus (VWR) slides and imaged with a Confocal
Microscope (Zeiss). Teratoma assays were performed as previously
described [56].
Genomic Southern Blotting
5 mg of genomic DNA from hiPSC samples growing in feeder-
free conditions was isolated with a DNeasy Blood & Tissue Kit
(QIAGEN), and digested with high fidelity restriction enzymes
BamHI and SpeI (NEB). Undigested ‘‘combination 6’’ pCEP4
episomal vectors (0.46: 8.55 pg of pEP4O2DEN2L, 9.72 pg of
pEP4EO2SET2K, 9.22 pg of pEP4EO2SEM2K) were mixed in
1:1:1 ratios and purified by QIAquick PCR Purification Kit
(QIAGEN). Samples were processed using DIG High Prime DNA
labeling and Detection Starter Kit II (Roche Applied Biosciences)
following the manufacturer’s directions. The pCEP4 parental
construct (Invitrogen) was digested with NotI and NruI (Invitro-
gen) to release a 7.3 kb episomal vector backbone probe, gel-
extracted using the QIAquick Gel Extraction Kit (Invitrogen),
DIG labeled, further digested with AluI (Invitrogen), and purified
using QIAquick PCR Purification Kit (QIAGEN).
Genomic PCR, semi-quantitative RT-PCR, and real-time
qRT-PCR
DNA was extracted using DNeasy Blood & Tissue and RNeasy
Mini Kits (QIAGEN). For hiPSC experiments, DNA and RNA
were extracted from p11 CBiPSC cells, negative control p48 H9
hESC, and positive p2 early CBiPSC, RT was performed using
SuperScript-First Strand Synthesis (Invitrogen), and PCR using Pfx
DNA polymerase (Invitrogen). Real-time RT-PCR was performed
Power SYBR PCR Mastermix (Applied Biosystems). Genomic
analysis for non-viral hiPSC used primers as described [25]. RT-
PCR analysis used primers as described [55]. For cardiomyocyte
analysis, the contents of 16 wells a 96-well plate were removed,
RNA extracted as above, cDNA synthesis was performed using a
High Capacity RNA-cDNA kit (Applied Biosystems, Carlsbad, CA,
http://www.appliedbiosystems.com). Real-time RT-PCR was per-
formed using Universal PCR Master Mix and on an Applied
Biosystems 7900HT. Using Taqman Assay-on-Demand Gene
Expression Assays (Applied Biosystems) (Table S1).
Cardiac differentiation
For forced aggregation hEB differentiations, confluent hESC or
hiPSC which had been grown on Geltrex as monolayers for 3 to 13
passages were passaged with TrypLE Select and seeded at 2.5610
6
per T25 flask. After 24 h growth, cells were treated with TrypLE
Select and seeded at 5000 cells per well in 96-well V-bottom
uncoated plates (249952, NUNC Rochester, NY, http://www.
nuncbrand.com) in100 mL per well RPMI+PVA medium consisting
of RPMI Media 1640 (with L-Glutamine), 4 mg mL
21 polyvinyl
alcohol (P8136 Sigma-Aldrich St. Louis MO, http://www.
sigmaaldrich.com), dissolved in RPMI at 4uC for at least 72 h,
mixing by inversion every day, 1% chemically defined lipid
concentrate, 10 mgm L
21 recombinant human insulin (I9278,
Sigma-Aldrich), 400 mM 1-thioglycerol (Sigma-Aldrich), 25 ng mL
21
human BMP4 and 5 ng mL
21 human FGF2 (both from R&D
systems), 1 mM Y-27632 (Stemgent, Cambridge, MA, http://www.
stemgent.com). Thismediumisnot stable and wasmade fresh for each
experiment. After 48 hours medium was aspirated with a Costar 8-
channel aspirator (Corning Life Sciences, Corning, NY, http://www.
corning.com) and replaced with RPMI+FBS medium consisting of
RPMI Media 1640, 20% FBS (Characterized, Hyclone), 400 mM1 -
thioglycerol. On day 4 media was aspirated and replaced with
RPMI+INS consisting of RPMI, 1% chemically defined lipid
concentrate, 10 mgm L
21 recombinant human insulin, 400 mM1 -
thioglycerol and hEB were transferred to 96-well U-bottom tissue
culture treated plates (NUNC). Media was changed on d7 and every 3
days afterwards. hEB were visually assessed for contraction on d9
using a Nikon Eclipse Ti microscope (Nikon Instruments, Melvin, NY,
http://www.nikoninstruments.com). Images were captured using
NIS-Elements (Nikon). Other factors that were tested include:
Germcell human serum, Benchmark FBS (Gemini, Sacramento,
CA, http://www.gembio.com), Growth factor reduced Matrigel (BD
B i o s c i e n c e s ) ,N O D A L ,a c t i v i nA ,D K K 1 ,V E G F A 165,W N T 3 A ,
TDGF1, BMP2, BMP6, TGFB, IGF1, IGF2, Nidogen (R&D
systems), 96-well U-bottom uncoated plates, 96-well F-bottom tissue
culture plates (NUNC), ITS-X, ITS-G, N2 supplement, B27
supplement, non-essential amino acids, DMEM, IMDM, F12, KO-
DMEM, StemPro-34, KnockOut Serum Replacement, Xeno-free
Knockout Serum Replacement, Qualified FBS (all from Invitrogen),
X-VIVO 10 (Lonza), BSA (A3311), human serum albumin (HSA),
recombinant human albumin (rHA), human transferrin, L-ascorbic
acid, L-ascorbic acid-2-phosphate, Stemline II (Sigma-Aldrich),
mTeSR1, SFEM, ES-Cult FBS for Hematopoietic Differentiation
(StemCell Technologies), mouse WNT3A, EX-CYTE (Millipore,
Billerica, MA, http://www.millipore.com). Traditional cardiac differ-
entiations using FBS were performed as previously described [6].
Briefly, confluent H9 hESC grown as colonies on MEF were treated
with collagenase IV for 5 min at 37uC then washed from the plate
using a 5 mL pipette. Cell clusters were then transferred to Petri dishes
in DMEM (with Glutamine), 20% FBS (Characterized, Hyclone), 1%
NEAA,100 mM2-mercaptethanolmediumfor7 days.hEB were then
transferred to gelatin coated tissue culture plates. Media was changed
every three days.
Statistical Design
One single replicate consists of one 96-well plate. Repeat
replicates were performed 1–4 months apart. Each experiment
was repeated .3 times representing .288 hEB. Total number of
hEB assessed in this work exceeds 80,000. Wells in which no hEB
was detected due to pipetting error were excluded and accounted
for approximately 1–5% of wells. P-values were established using
an unpaired two-tailed Student’s t-test.
Cardiomyocyte immunocytochemistry and flow
cytometry analysis
Whole cardiomyocyte hEB clusters were plated onto fibronec-
tin-coated glass coverslips and given 5 days to attach and
processed as above with primary antibodies anti human
sarcomeric alpha actinin (1:200, monoclonal mouse IgG1,
ab9465, Abcam, Cambridge, MA, http://www.abcam.com) and
anti-human cardiac troponin I (1:200, monoclonal mouse IgG2b,
T8665-13F, US Biological, Swamscott, MA, http://www.usbio.
net) and secondary antibodies Alexa Fluor 568 Goat anti-mouse
IgG (1:200, Invitrogen) and Alexa Fluor 488 Goat anti-mouse
IgG2b (1:200, Invitrogen). For flow cytometry, one whole plate of
d9 H9 hEB (whole well contents) were disaggregated using
TrypLE and stained as above. Cells were analyzed using a
FACSCaliber (BD Biosciences) flow cytometer (Beckton-Dick-
inson). Data was analyzed using FlowJo (Tree Star, Ashland, OR,
http://www.treestar.com).
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For optical micromapping, contracting hEB were mechanically
dissected, plated on fibronectin (BD Biosciences)-coated glass
coverslips and given at least 5 days to attach. hEB were then
stained with either 10 mM Rhod-2-AM calcium dye (Invitrogen)
for 20 minutes or 10 mM di-4-ANEPPS voltage dye (Invitrogen)
for 5 minutes. After several rinses with Tyrode’s solution
(135 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2,
0.33 mM NaH2PO4, 5 mM HEPES, and 5 mM glucose,
(Sigma)), hEB were incubated with 30 mM blebbistatin (Sigma)
for 15 minutes to inhibit excitation-contraction coupling and
subsequently prevent signal distortion due to motion artifact. The
absence of hEB contraction was confirmed visually. hEB were
then excited at 530 nm to visualize spontaneous activity and
response to electrical field stimulation. Imaging of transmem-
brane potential (Vm) or intracellular calcium (Cai) was performed
using an Andor iXon+ 860 (Andor Technology, South Windsor,
CN, http://www.andor.com) electron multiplying charged cou-
pled device (EMCCD) camera (1286128 pixels) at 490 Hz
sampling rate. At 66 magnification, the field of view is
,520 mm6520 mm, resulting in a spatial resolution of ,4 mm.
Micromapping experiments were performed at room tempera-
ture. Macromapping of hESC-CM monolayers was performed
using contact fluorescent imaging, in which maps of Vm were
recorded by placing the monolayer directly on top of a bundle of
253 optical fibers 1 mm in diameter, arranged in a tightly
packed, 17-mm-diameter hexagonal array. The cell monolayers
were stained with 10 mM di-4-ANEPPS, and continually
superfused with Tyrode’s solution. The monolayer was excited
by an array of high-power green LEDs placed directly above the
experimental chamber. The fluorescent dye signal was relayed by
the optical fiber bundle to an array of photodetectors and
amplifiers, digitized at a 1 kHz sampling rate, and processed by
custom written software. Macromapping experiments were
performed at 36uC. In drug-response experiments, drugs were
added for 15 min before subsequent recordings. To analyze data,
the individual recorded signals were spatially filtered using a 565
box filter, temporally filtered using a 10 point median filter,
baseline-corrected by subtraction of a fitted 3
rd order polynomial,
and range-normalized. The activation time at each recording site
was computed as the time of the maximum first derivative of the
action potential (dVm/dtmax) or calcium transient upstroke (dCa/
dtmax). Repolarization time was computed as the 80% recovery
time from the peak amplitude, and action potential duration
(APD) was computed from the difference of repolarization and
activation times. APD maps were computed by first spatially
binning voltage data to 16616 pixels and measuring APD at each
pixel. Uniformity of APD was assessed by the coefficient of
variation. For each hEB, the coefficient of variation was
determined from the mean APD (over all pixels in the APD
map), divided by the standard deviation. Conduction velocity was
computed by taking the distance of a path perpendicular to the
direction of propagation, and dividing by the difference of
activation times at the path endpoints. At least 3 paths were
chosen for each measurement. The conduction velocity coeffi-
cient of variation was determined from the mean conduction
velocity (over all measured paths), divided by the standard
deviation.
Supporting Information
Figure S1 Schematic representation of the variables considered
whilst optimizing the cardiac differentiation system.
(TIF)
Figure S2 Development of a strategy for the optimization of
cardiac differentiation. (A) Schematic of previous cardiac differ-
entiation strategy published in Burridge et al., 2007. (B) Pilot
experiments allowed us to develop a prototype system in which we
used BMP4 from d0–d4 and removed the mass culture step to
eliminate the inter-hEB paracrine effect and prevents hEB from
adhering to each other. (C) Final four step optimized differenti-
ation strategy detailing the use of hESC/hIPSC passaged one day
prior to aggregation, 5,000 cells in RPMI+PVA media for 2 days
followed by 2 days in RPMI+FBS and finally adherence in
RPMI+INS. All variables previously tested between the prototype
system stage and final system were repeated three times to confirm
dose-response under final system conditions.
(TIF)
Figure S3 Optimizing media formulations of hEB formation. (A)
21 existing media formulations werecompared for efficiency of hEB
formation both from cells cultured as colonies on MEF and cells
grown as monolayers. hEB were formed from 10,000 cells, collected
into a single well on d2 and imaged (46magnification). The results
demonstrated that media formulation from Wiles & Johansson ’98
was most successful for homogeneous hEB formation. (B)T h e
minimal media requirements for hEB formation were assessed by
subtraction until we found that only the combination of a basal
medium supplemented with 1 mg mL
21 PVA and insulin was
required for successful hEB formation (46magnification). Details of
references are provided in References S1.
(TIF)
Figure S4 Optimization of day 0–2 media formulation and
growth factor variables using H9 hESC. d9 was chosen for
assessment as ‘prototype’ version of our previous protocol had
identified this as the day of maximum percentage contraction.
Optimal conditions for the d0–d2 phase 2 stage were derived using
RPMI-PVA as the base media (Table 1) and making relevant
subtractions or additions to it. Optimal conditions for high
efficiency differentiation differentiation were: (A)2 5n gm L
21 of
BMP4. (B) 5 ng ml
21 FGF2. (C) The basal medium RPMI 1640.
(D) No additional L-glutamine other than that included in the
basal medium (2.5 mM). (E) 400 mM 1-thioglycerol was optimal
for cardiac differentiation whereas 2-mercaptoethanol was not
suitable for hEB formation. (F)1 0mgm L
21 insulin, more complex
products such as ITS-G or -X (Invitrogen) provided similar results.
(G) The addition of transferrin did not affect differentiation. (H)L -
ascorbic acid had a negative dose-response on differentiation. (I)
16chemically defined lipids. (J) non-essential amino acids did not
enhance differentiation. (K) The addition of BSA alone did not
promote differentiation although PVA was successful at a
concentration of .1m gm L
21.( L) Only a comparatively low
dose of 1 mM of Y-27632 (ROCK inhibitor) promoted efficient
subsequent differentiation. n=3. Error bars, 6S.E.M.
(TIF)
Figure S5 Optimization of forced aggregation hEB formation
physical factors. Optimal conditions for physical factors stage were
derived using system described in Figure 1A and making relevant
subtractions or additions to it. (A) Forced aggregation input cell
number per well between 500–20,000 cells. 3,000–10,000 cells
were suitable for successful cardiac differentiation. hEB did not
form from 500 or 1,000 cells. (B) Both V-bottom and U-bottom
plates were successful for hEB formation, V-bottom plates were
chosen due to the comparative ease of media change and
prevention of loss of hEB. (C) Only day 2 was suitable for change
of media RPMI-FBS. (D) hEB that were transferred to adherent
plates before d4 quickly lost their structure. (E) U-bottom plates
were chosen over F-bottom plates as hEB would adhere in the
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(F) Once Y-27632 was added to the media it was found that g-
force was no longer required to induce aggregation. (G) The
density at which the T25 flasks of pluripotent cells were split to the
day before forced aggregation did not affect subsequent differen-
tiation. (H) Passaging cells one day prior to forced aggregation
rather than allowing them to grow to confluence was found to be
crucial for efficient differentiation. n=3. Error bars, 6S.E.M.
(TIF)
Figure S6 Optimization of day 2–4 media factors. (A) Only 20%
fetal bovine serum (FBS) was suitable for inducing .90%
contracting hEB. Optimal conditions for the d2–d4 phase 3 stage
were derived using RPMI-FBS as the base media (Table 1) and
making relevant subtractions or additions to it. (B) Manufacturer
of FBS did not affect cardiac induction. FBS could be substituted
with 20% human serum with no reduction in efficiency to create a
fully xeno-free system. The use of Knockout Serum Replacement
(KSR) or Xeno-Free KSR was not sufficient to allow cardiomy-
ocyte induction. (C) The addition of BMP4 at this d2–d4 stage did
not enhance cardiac differentiation. (D) The addition of FGF2 also
did not have an effect on cardiac differentiation. (E) As with d0–
d2, only the basal medium RPMI was suitable for efficient cardiac
differentiation. (F) Additional L-glutamine did not enhance
cardiac differentiation. (G) 1-thioglycerol was the most suitable
thiol for this phase. (H) Any level of supplementation with insulin
during this phase completely ablated cardiac differentiation. (I)
Human transferrin did not enhance differentiation. (J) L-ascorbic
acid did not enhance differentiation at low dose although did have
a negative effect on differentiation at high doses (560 mM). (K)
Chemically defined lipids dis not enhance differentiation although
EX-CYTE (Millipore) had a negative effect. (L) Non-essential
amino acids (NEAA) did not enhanced this phase of differentia-
tion. n=3. Error bars, 6S.E.M.
(TIF)
Figure S7 Optimization of day 4 onwards media formulation.
Optimal conditions for the d0–d2 phase 2 stage were derived using
RPMI-INS as the base media (Table 1) and making relevant
subtractions or additions to it. (A) FBS, PVA or HSA was not
required for the d4 onwards phase. (B) In contrast to the d2–d4
stage, insulin did not effect this d4+ phase. (C) Transferrin was not
required. (D) Supplemental lipids were also not required. (E)1 -
thioglycerol was essential for this d4+ phase. Although only
RPMI+1-thioglycerol was required for d4+ cardiac differentiation,
a more complex media (RPMI-INS) was required for further (d9
onwards) hEB survival and therefore used in the final system.
n=3. Error bars, 6S.E.M.
(TIF)
Figure S8 Demonstration of cardiomyocyte drug responsiveness
and electrical coupling using optical mapping. (A) Time series of
voltage maps demonstrates electrical coupling in an hESC-derived
cardiomyocyte monolayer during 0.67 Hz pacing (pulse symbol
indicates stimulus site, arrows indicate direction of propagation). A
second, spontaneous activation site can seen on the upper right at
40 ms. b, Representative Vm traces, time aligned by the stimulus
timing, taken at site x in a. Isoproterenol and pinacidil shortened
the action potential (3636137 ms control (n=73 recording sites)
vs. 257656 ms pinacidil (n=64) vs. 2626107 ms isoproterenol
(n=94), mean6s.d.). (B) Electrical coupling between two hEB
during voltage micromapping. a, Phase map of two hEB in close
contact at 66. b, Time series of voltage maps demonstrates
electrical coupling between the hEB pair by continuous propaga-
tion from one hEB to the other. c and d, Vm traces (from the three
boxes in a) demonstrate the synchrony of the action potentials, as
the electrical wave propagates from right to left (red to blue to
green trace) across the field of view.
(TIF)
Figure S9 Optimization of xeno- and serum-free day 2–4 media
formulation. Optimal conditions for the d2–d4 phase 2 stage were
derived using ‘Xeno-free’ as the base media (Table 1) and making
relevant subtractions or additions to it. (A) PVA supplementation did
not induce cardiac differentiation. (B) A high dose (5 mg mL
21)o f
human serum albumin (HSA) was required. (C) HSA could not be
replaced by recombinant albumin. (D) As with the xeno-containing
d2–d4 media formulation, the addition of insulin inhibited cardiac
differentiation. (E) The addition of transferrin did not impact
differentiation. (F) L-ascorbic acid promoted xeno-free cardiac
differentiation any concentration. (G) Chemically defined lipids had
a small effect. (H) Non-essential amino acids were not required. This
xeno-free d2–d4 media could also be simply replaced by the BSA-
containing media StemPro34 (Invitrogen) supplemented with
280 mM of L-ascorbic acid with similar results (data not shown).
(TIF)
Table S1 Real-time RT-PCR primers. Table of Applied
Biosystems assay-on-demand primers used for real-time RT-
PCR analysis.
(TIF)
Table S2 Heat-map of optimized media formulations and
physical factors for cardiac differentiation of H9 hESC. A
condensed schematic of the optimal cardiac differentiation media
formulations and physical factors used in the optimized protocol.
Red represents greater than 90% of hEB contracting on d9, yellow
represents 50–90% of hEB contracting on d9, blue represents less
than 50% of hEB contracting on d9, and white represents 0%
contracting hEB on d9.
(TIF)
Movie S1 Contracting H9 hEB on d9 of differentiation.
(MOV)
Movie S2 Contracting iPS(IMR90)-1 hEB on d9 of differentiation.
(MP4)
Movie S3 Voltage mapping of H9 hEB.
(MP4)
Movie S4 Calcium mapping of H9 hEB.
(MP4)
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